{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:28:47Z","timestamp":1791264527979,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1186\/bcr2835","type":"journal-article","created":{"date-parts":[[2011,5,19]],"date-time":"2011-05-19T06:18:47Z","timestamp":1305785927000},"source":"Crossref","is-referenced-by-count":97,"title":["Therapeutic targets for bone metastases in breast cancer"],"prefix":"10.1186","volume":"13","author":[{"given":"Philippe","family":"Cl\u00e9zardin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,4,6]]},"reference":[{"key":"2670_CR1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nrc2621","volume":"9","author":"B Psaila","year":"2009","unstructured":"Psaila B, Lyden D: The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 2009, 9: 285-293. 10.1038\/nrc2621.","journal-title":"Nat Rev Cancer"},{"key":"2670_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002, 2: 584-593. 10.1038\/nrc867.","journal-title":"Nat Rev Cancer"},{"key":"2670_CR3","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10585-007-9112-8","volume":"24","author":"P Cl\u00e9zardin","year":"2007","unstructured":"Cl\u00e9zardin P, Teti A: Bone metastasis: pathogenesis and therapeutic implications. Clin Exp Metastasis. 2007, 24: 599-608. 10.1007\/s10585-007-9112-8.","journal-title":"Clin Exp Metastasis"},{"key":"2670_CR4","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ccr.2010.12.022","volume":"19","author":"N Sethi","year":"2011","unstructured":"Sethi N, Dai X, Winter CG, Kang Y: Tumor-derived jagged1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 2011, 19: 192-205. 10.1016\/j.ccr.2010.12.022.","journal-title":"Cancer Cell"},{"key":"2670_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1196\/annals.1443.016","volume":"1143","author":"A Leibbrandt","year":"2008","unstructured":"Leibbrandt A, Penninger JM: RANK\/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci. 2008, 1143: 123-150. 10.1196\/annals.1443.016.","journal-title":"Ann N Y Acad Sci"},{"key":"2670_CR6","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/jcp.22272","volume":"225","author":"G Leto","year":"2010","unstructured":"Leto G: Activin A and bone metastasis. J Cell Physiol. 2010, 225: 302-309. 10.1002\/jcp.22272.","journal-title":"J Cell Physiol"},{"key":"2670_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.bone.2010.07.016","volume":"48","author":"P Cl\u00e9zardin","year":"2011","unstructured":"Cl\u00e9zardin P: Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class. Bone. 2011, 48: 71-79. 10.1016\/j.bone.2010.07.016.","journal-title":"Bone"},{"key":"2670_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1210\/er.2007-0014","volume":"29","author":"AE Kearns","year":"2008","unstructured":"Kearns AE, Khosla S, Kostenuik PJ: Receptor of nuclear factor kB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008, 29: 155-192. 10.1210\/er.2007-0014.","journal-title":"Endocr Rev"},{"key":"2670_CR9","doi-asserted-by":"publisher","first-page":"5558","DOI":"10.1158\/0008-5472.CAN-09-4416","volume":"70","author":"AL Sabbota","year":"2010","unstructured":"Sabbota AL, Kim HRC, Zhe X, Fridman R, Bonfil RD, Cher ML: Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration. Cancer Res. 2010, 70: 5558-5566. 10.1158\/0008-5472.CAN-09-4416.","journal-title":"Cancer Res"},{"key":"2670_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nature09495","volume":"468","author":"E Gonzalez-Suarez","year":"2010","unstructured":"Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dougall WC: RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature. 2010, 468: 103-107. 10.1038\/nature09495.","journal-title":"Nature"},{"key":"2670_CR11","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GS, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010, 28: 5132-5139. 10.1200\/JCO.2010.29.7101.","journal-title":"J Clin Oncol"},{"key":"2670_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1470-2045(10)70010-3","volume":"11","author":"D Thomas","year":"2010","unstructured":"Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S: Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010, 11: 275-280. 10.1016\/S1470-2045(10)70010-3.","journal-title":"Lancet Oncol"},{"key":"2670_CR13","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1083\/jcb.200611083","volume":"176","author":"w Zou","year":"2007","unstructured":"Zou w, Kitaura H, Reeve J, Long F, Tybulewicz VLJ, Shattil SJ, Ginsberg MH, Ross FP, Teitelbaum SL: Syk, c-Src, the avb3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J Cell Biol. 2007, 176: 877-888. 10.1083\/jcb.200611083.","journal-title":"J Cell Biol"},{"key":"2670_CR14","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2174\/156800909789760348","volume":"9","author":"P Cl\u00e9zardin","year":"2009","unstructured":"Cl\u00e9zardin P: Integrins in bone metastasis formation and potential therapeutic implications. Curr Cancer Drug Targets. 2009, 9: 801-806. 10.2174\/156800909789760348.","journal-title":"Curr Cancer Drug Targets"},{"key":"2670_CR15","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1002\/ijc.25563","volume":"128","author":"T B\u00e4uerle","year":"2010","unstructured":"B\u00e4uerle T, Komljenovic D, Merz M, Berger MR, Goodman SL, Semmler W: Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study. Int J Cancer. 2010, 128: 2453-2462.","journal-title":"Int J Cancer"},{"key":"2670_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2748","volume":"10","author":"JS Desgrosellier","year":"2010","unstructured":"Desgrosellier JS, Cheresh DA: Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010, 10: 9-22. 10.1038\/nrc2748.","journal-title":"Nat Rev Cancer"},{"key":"2670_CR17","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1210\/jc.2004-2126","volume":"90","author":"MG Murphy","year":"2005","unstructured":"Murphy MG, Cerchio K, Stoch SA, Gottesdiener K, Wu M, Recker R: Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab. 2005, 90: 2022-2028. 10.1210\/jc.2004-2126.","journal-title":"J Clin Endocrinol Metab"},{"key":"2670_CR18","doi-asserted-by":"publisher","first-page":"6291s","DOI":"10.1158\/1078-0432.CCR-06-0991","volume":"12","author":"BF Boyce","year":"2006","unstructured":"Boyce BF, Xing L, Yao Z, Yamashita T, Shakespeare WC, Wang Y, Metcalf CA, Sundaramoorthi R, Dalgarno DC, Iuliucci JD, Sawyer TK: SRC inhibitors in metastatic bone disease. Clin Cancer Res. 2006, 12: 6291s-6295s. 10.1158\/1078-0432.CCR-06-0991.","journal-title":"Clin Cancer Res"},{"key":"2670_CR19","doi-asserted-by":"publisher","first-page":"14205","DOI":"10.1073\/pnas.2234372100","volume":"100","author":"SJ Bakewell","year":"2003","unstructured":"Bakewell SJ, Nestor P, Prasad S, Tomasson MH, Dowland N, Mehrotra M, Scarborough R, Kanter J, Abe K, Phillips D, Weilbaecher KN: Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci USA. 2003, 100: 14205-14210. 10.1073\/pnas.2234372100.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2670_CR20","first-page":"5028","volume":"63","author":"A Myoui","year":"2003","unstructured":"Myoui A, Nishimura R, Williams PJ, Hiraga T, Tamura D, Michigami T, Mundy GR, Yoneda T: C-Src tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer bone metastasis. Cancer Res. 2003, 63: 5028-5033.","journal-title":"Cancer Res"},{"key":"2670_CR21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1124\/jpet.106.102004","volume":"318","author":"N Rucci","year":"2006","unstructured":"Rucci N, Recchia I, Angelucci A, Alamanou M, Del Fattore A, Fortunati D, Susa M, Fabbro D, Bologna M, Teti A: Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J Pharmacol Exp Ther. 2006, 318: 161-172. 10.1124\/jpet.106.102004.","journal-title":"J Pharmacol Exp Ther"},{"key":"2670_CR22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ccr.2009.05.017","volume":"16","author":"XH Zhang","year":"2009","unstructured":"Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, Foekens JA, Massagu\u00e9 J: Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell. 2009, 16: 67-78. 10.1016\/j.ccr.2009.05.017.","journal-title":"Cancer Cell"},{"key":"2670_CR23","doi-asserted-by":"publisher","first-page":"4876","DOI":"10.1158\/1078-0432.CCR-10-0748","volume":"16","author":"J Baselga","year":"2010","unstructured":"Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI, Jodrell DI, Hamberg P, Casado E, Elvin P, Swaisland A, Iacona R, Tabernero J: Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin Cancer Res. 2010, 16: 4876-4883. 10.1158\/1078-0432.CCR-10-0748.","journal-title":"Clin Cancer Res"},{"key":"2670_CR24","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nrclinonc.2009.129","volume":"6","author":"LC Kim","year":"2009","unstructured":"Kim LC, Song L, Haura EB: SRC kinases as therapeutic targets for cancer. Nat Rev Clin Oncol. 2009, 6: 587-595. 10.1038\/nrclinonc.2009.129.","journal-title":"Nat Rev Clin Oncol"},{"key":"2670_CR25","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/SPC.0b013e32830baea9","volume":"2","author":"C Le Gall","year":"2008","unstructured":"Le Gall C, Bonnelye E, Cl\u00e9zardin P: Cathepsin K inhibitors as treatment of bone metastasis. Curr Opin Support Palliat Care. 2008, 2: 218-222. 10.1097\/SPC.0b013e32830baea9.","journal-title":"Curr Opin Support Palliat Care"},{"key":"2670_CR26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.bone.2007.09.044","volume":"42","author":"K Fuller","year":"2008","unstructured":"Fuller K, Lawrence KM, Ross JL, Grabowska UB, Shiroo M, Samuelsson B, Chambers TJ: Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts. Bone. 2008, 42: 200-211. 10.1016\/j.bone.2007.09.044.","journal-title":"Bone"},{"key":"2670_CR27","doi-asserted-by":"publisher","first-page":"9894","DOI":"10.1158\/0008-5472.CAN-06-3940","volume":"67","author":"C Le Gall","year":"2007","unstructured":"Le Gall C, Bellahc\u00e8ne A, Bonnelye E, Gasser JA, Castronovo V, Green J, Zimmermann J, Cl\u00e9zardin P: A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res. 2007, 67: 9894-9902. 10.1158\/0008-5472.CAN-06-3940.","journal-title":"Cancer Res"},{"key":"2670_CR28","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3816\/CBC.2010.n.059","volume":"10","author":"AB Jensen","year":"2010","unstructured":"Jensen AB, Wynne C, Ramirez G, He W, Song Y, Berd Y, Wang H, Mehta A, Lombardi A: The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clin Breast Cancer. 2010, 10: 452-458. 10.3816\/CBC.2010.n.059.","journal-title":"Clin Breast Cancer"},{"key":"2670_CR29","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nrrheum.2009.175","volume":"5","author":"Y Choi","year":"2009","unstructured":"Choi Y, Arron JR, Townsend MJ: Promising bone-related therapeutic targets for rheumatoid arthritis. Nat Rev Rheumatol. 2009, 5: 543-548. 10.1038\/nrrheum.2009.175.","journal-title":"Nat Rev Rheumatol"},{"key":"2670_CR30","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1056\/NEJMoa030847","volume":"349","author":"E Tian","year":"2003","unstructured":"Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD: The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003, 349: 2483-2494. 10.1056\/NEJMoa030847.","journal-title":"N Engl J Med"},{"key":"2670_CR31","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","volume":"114","author":"M Fulciniti","year":"2009","unstructured":"Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, Shen Z, Patel N, Tai YT, Chauhan D, Mitsiades C, Prabhala R, Raje N, Anderson KC, Stover DR, Munshi NC: Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009, 114: 371-379. 10.1182\/blood-2008-11-191577.","journal-title":"Blood"},{"key":"2670_CR32","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","volume":"109","author":"S Yaccoby","year":"2007","unstructured":"Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD: Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 2007, 109: 2106-2111. 10.1182\/blood-2006-09-047712.","journal-title":"Blood"},{"key":"2670_CR33","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/sj.bjc.6603959","volume":"97","author":"N Voorzanger-Rousselot","year":"2007","unstructured":"Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ, Cl\u00e9zardin P, Garnero P: Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer. 2007, 97: 964-970.","journal-title":"Br J Cancer"},{"key":"2670_CR34","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/ijc.23625","volume":"123","author":"G Bu","year":"2008","unstructured":"Bu G, Lu W, Liu CC, Selander K, Yoneda T, Hall C, Keller ET, Li Y: Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases. Int J Cancer. 2008, 123: 1034-1042. 10.1002\/ijc.23625.","journal-title":"Int J Cancer"},{"key":"2670_CR35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nrd3299","volume":"10","author":"M Kawai","year":"2011","unstructured":"Kawai M, M\u00f6dder UI, Khosla S, Rosen CJ: Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov. 2011, 10: 141-156. 10.1038\/nrd3299.","journal-title":"Nat Rev Drug Discov"},{"key":"2670_CR36","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/jcp.22272","volume":"225","author":"G Leto","year":"2010","unstructured":"Leto G: Activin A and bone metastasis. J Cell Physiol. 2010, 225: 302-309. 10.1002\/jcp.22272.","journal-title":"J Cell Physiol"},{"key":"2670_CR37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10585-006-9010-5","volume":"23","author":"G Leto","year":"2006","unstructured":"Leto G, Incorvaia L, Badalamenti G, Tumminello FM, Gebbia N, Flandina C, Crescimanno M, Rini G: Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis. 2006, 23: 117-122. 10.1007\/s10585-006-9010-5.","journal-title":"Clin Exp Metastasis"},{"key":"2670_CR38","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1002\/jbmr.142","volume":"25","author":"AD Chantry","year":"2010","unstructured":"Chantry AD, Heath D, Mulivor AW, Pearsall S, Baud'huin M, Coulton L, Evans H, Abdul N, Werner ED, Bouxsein ML, Key ML, Seehra J, Arnett TR, Vanderkerken K, Croucher P: Inhibiting activin-A signaling stimulates bone formation and prevents cancer induced bone destruction in vivo. J Bone Miner Res. 2010, 25: 2633-2646. 10.1002\/jbmr.142.","journal-title":"J Bone Miner Res"},{"key":"2670_CR39","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrc990","volume":"3","author":"J Nelson","year":"2003","unstructured":"Nelson J, Bagnato A, Battistini B, Nisen P: The endothelin axis: emerging role in cancer. Nat Rev Cancer. 2003, 3: 110-116. 10.1038\/nrc990.","journal-title":"Nat Rev Cancer"},{"key":"2670_CR40","doi-asserted-by":"publisher","first-page":"10954","DOI":"10.1073\/pnas.1830978100","volume":"100","author":"JJ Yin","year":"2003","unstructured":"Yin JJ, Mohammad KS, K\u00e4k\u00f6nen SM, Harris S, Wu-Wong JR, Wessale JL, Padley RJ, Garrett IR, Chirgwin JM, Guise TA: A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA. 2003, 100: 10954-10959. 10.1073\/pnas.1830978100.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2670_CR41","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10585-006-9016-z","volume":"23","author":"D Dr\u00e9au","year":"2006","unstructured":"Dr\u00e9au D, Karaa A, Culberson C, Wyan H, McKillop IH, Clemens MG: Bosentan inhibits tumor vascularization and bone metastasis in an immunocompetent skin-fold chamber model of breast carcinoma cell metastasis. Clin Exp Metastasis. 2006, 23: 41-53. 10.1007\/s10585-006-9016-z.","journal-title":"Clin Exp Metastasis"},{"key":"2670_CR42","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1158\/0008-5472.CAN-03-1069","volume":"64","author":"MJ Grimshaw","year":"2004","unstructured":"Grimshaw MJ, Hagemann T, Ayhan A, Gillett CE, Binder C, Balkwill FR: A role for endothelin-2 and its receptors in breast tumor cell invasion. Cancer Res. 2004, 64: 2461-2468. 10.1158\/0008-5472.CAN-03-1069.","journal-title":"Cancer Res"},{"key":"2670_CR43","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.1158\/1078-0432.CCR-10-0600","volume":"16","author":"S Vallet","year":"2010","unstructured":"Vallet S, Smith MR, Raje N: Novel bone-targeted strategies in oncology. Clin Cancer Res. 2010, 16: 4084-4093. 10.1158\/1078-0432.CCR-10-0600.","journal-title":"Clin Cancer Res"},{"key":"2670_CR44","unstructured":"AstraZeneca halts phase III trial of ZIBOTENTAN in non-metastatic castrate resistant prostate cancer. [ http:\/\/www.astrazeneca.com\/Media\/Press-releases\/Article\/0022011AstraZeneca-halts-phase-III-trial-of-ZIBOTENTAN ]"},{"key":"2670_CR45","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.2174\/138161210791034049","volume":"16","author":"P Ju\u00e1rez","year":"2010","unstructured":"Ju\u00e1rez P, Guise TA: TGFb pathway as a therapeutic target in bone metastases. Curr Pharm Des. 2010, 16: 1301-1312. 10.2174\/138161210791034049.","journal-title":"Curr Pharm Des"},{"key":"2670_CR46","doi-asserted-by":"publisher","first-page":"e6896","DOI":"10.1371\/journal.pone.0006896","volume":"4","author":"LK Dunn","year":"2009","unstructured":"Dunn LK, Mohammad KS, Fournier PG, McKenna CR, Davis HW, Niewolna M, Peng XH, Chirgwin JM, Guise TA: Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One. 2009, 4: e6896-10.1371\/journal.pone.0006896.","journal-title":"PLoS One"},{"key":"2670_CR47","doi-asserted-by":"publisher","first-page":"e10365","DOI":"10.1371\/journal.pone.0010365","volume":"5","author":"A Bandyopadhyay","year":"2010","unstructured":"Bandyopadhyay A, Wang L, Agyin J, Tang Y, Lin S, Yeh IT, De K, Sun LZ: Doxorubicin in combination with a small TGFb inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PloS One. 2010, 5: e10365-10.1371\/journal.pone.0010365.","journal-title":"PloS One"},{"key":"2670_CR48","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","volume":"139","author":"JP Thiery","year":"2009","unstructured":"Thiery JP, Acloque H, Huang RY, Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 2009, 139: 871-890. 10.1016\/j.cell.2009.11.007.","journal-title":"Cell"},{"key":"2670_CR49","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.2353\/ajpath.2007.070168","volume":"171","author":"JT Buijs","year":"2007","unstructured":"Buijs JT, Rentsch CA, van der Horst G, van Overveld PG, Wetterwald A, Schwaninger R, Henriquez NV, Ten Dijke P, Borovecki F, Markwalder R, Thalmann GN, Papapoulos SE, Pelger RC, Vukicevic S, Cecchini MG, L\u00f6wik CW, van der Pluijm G: BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol. 2007, 171: 1047-1057. 10.2353\/ajpath.2007.070168.","journal-title":"Am J Pathol"},{"key":"2670_CR50","doi-asserted-by":"publisher","first-page":"8742","DOI":"10.1158\/0008-5472.CAN-06-2490","volume":"67","author":"JT Buijs","year":"2007","unstructured":"Buijs JT, Henriquez NV, van Overveld PG, van der Horst G, Que I, Schwaninger R, Rentsch C, Ten Dijke P, Cleton-Jansen AM, Driouch K, Lidereau R, Bachelier R, Vukicevic S, Cl\u00e9zardin P, Papapoulos SE, Cecchini MG, L\u00f6wik CW, van der Pluijm G: Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res. 2007, 67: 8742-8751. 10.1158\/0008-5472.CAN-06-2490.","journal-title":"Cancer Res"},{"key":"2670_CR51","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.2174\/138161210791034012","volume":"16","author":"AC Hirbe","year":"2010","unstructured":"Hirbe AC, Morgan EA, Weilbaecher KN: The CXCR4\/SDF-1 chemokine axis: a potential therapeutic target for bone metastases?. Curr Pharm Des. 2010, 16: 1284-1290. 10.2174\/138161210791034012.","journal-title":"Curr Pharm Des"},{"key":"2670_CR52","first-page":"761","volume":"21","author":"MM Richert","year":"2009","unstructured":"Richert MM, Vaidya KS, Mills CN, Wong D, Korz W, Hurst DR, Welch DR: Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol Rep. 2009, 21: 761-767.","journal-title":"Oncol Rep"},{"key":"2670_CR53","doi-asserted-by":"publisher","first-page":"7975","DOI":"10.1158\/1078-0432.CCR-07-4846","volume":"14","author":"D Wong","year":"2008","unstructured":"Wong D, Korz W: Translating an antagonist of chemokine receptor CXCR4: from bench to bedside. Clin Cancer Res. 2008, 14: 7975-7980. 10.1158\/1078-0432.CCR-07-4846.","journal-title":"Clin Cancer Res"},{"key":"2670_CR54","doi-asserted-by":"publisher","first-page":"14062","DOI":"10.1073\/pnas.0705203104","volume":"104","author":"AC Hirbe","year":"2007","unstructured":"Hirbe AC, Rubin J, Ulu\u00e7kan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, Weilbaecher KN: Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone. Proc Natl Acad Sci USA. 2007, 104: 14062-14067. 10.1073\/pnas.0705203104.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2670_CR55","unstructured":"Servier Medical Art. [ http:\/\/www.servier.com\/Smart\/ImageBank.aspx?id_=729 ]"},{"key":"2670_CR56","unstructured":"ClinicalTrials.gov. [ http:\/\/www.clinicaltrials.gov\/ ]"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/bcr2835.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/bcr2835\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/bcr2835.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T22:26:38Z","timestamp":1560205598000},"score":1,"resource":{"primary":{"URL":"http:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/bcr2835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["2670"],"URL":"https:\/\/doi.org\/10.1186\/bcr2835","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4]]},"article-number":"207"}}